Anzeige
Mehr »
Donnerstag, 14.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JWL4 | ISIN: NO0010598683 | Ticker-Symbol: HBQ
Stuttgart
14.05.26 | 08:05
0,096 Euro
0,00 % 0,000
1-Jahres-Chart
HOFSETH BIOCARE ASA Chart 1 Jahr
5-Tage-Chart
HOFSETH BIOCARE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1060,13708:30

Aktuelle News zur HOFSETH BIOCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.04.Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas211HBC announces the publication of its head-to-head clinical trial results with its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo® increased the Omega 3 Index (O3I) by over...
► Artikel lesen
27.03.Hofseth BioCare ASA: HBC ANNUAL REPORT 20251
13.02.Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT719HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up...
► Artikel lesen
11.02.Hofseth Biocare ASA: Notification of major shareholdings2
15.12.25Hofseth BioCare ASA: Cancellation of Subsequent Offering - Update on completion of Private Placement2
HOFSETH BIOCARE Aktie jetzt für 0€ handeln
03.12.25Hofseth BioCare ASA: Financial calendar-
21.11.25Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION3
21.11.25Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING2
20.11.25Hofseth BioCare ASA: Extraordinary General Meeting completed2
20.11.25Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING3
20.11.25Hofseth BioCare ASA: HBC ANNOUNCES STRATEGIC PRODUCT PARTNERSHIP WITH JAMES LAVALLE & METABOLIC ELITE-
07.11.25Hofseth Biocare ASA: Third Quarter 2025 Financial Report254HBC recorded total operating revenues of NOK 54.9 million in the third quarter of 2025, compared to NOK 67.9 million in the same period last year. Net operating revenues were NOK 54.8 million, reflecting...
► Artikel lesen
28.10.25XFRA CAPITAL ADJUSTMENT INFORMATION - 28.10.2025379Das Instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY wird ex Kapitalmassnahme gehandelt am 28.10.2025 The instrument 5YW CA07135M2031 BATTERY X METALS INC. EQUITY is traded ex capital adjustment...
► Artikel lesen
24.10.25Hofseth Biocare ASA: USD 5 Million Divestment in Aecorbio253NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
24.10.25Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio426NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION...
► Artikel lesen
09.09.25Hofseth Biocare ASA: ProGo, the world's first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways193HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs...
► Artikel lesen
22.08.25Hofseth Biocare ASA: Second Quarter 2025 Financial Report251HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared...
► Artikel lesen
16.05.25Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT848HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1